ZSANQ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ZSANQ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Zosano Pharma's change in receivables for the quarter that ended in Mar. 2022 was $-1.49 Mil. It means Zosano Pharma's Accounts Receivable increased by $1.49 Mil from Dec. 2021 to Mar. 2022 .
Zosano Pharma's change in receivables for the fiscal year that ended in Dec. 2021 was $-0.11 Mil. It means Zosano Pharma's Accounts Receivable increased by $0.11 Mil from Dec. 2020 to Dec. 2021 .
Zosano Pharma's Accounts Receivable for the quarter that ended in Mar. 2022 was $0.09 Mil.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Zosano Pharma's Days Sales Outstanding for the three months ended in Mar. 2022 was 62.91.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Zosano Pharma's liquidation value for the three months ended in Mar. 2022 was $1.21 Mil.
The historical data trend for Zosano Pharma's Change In Receivables can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zosano Pharma Annual Data | |||||||||||||||||||||
Trend | Dec12 | Dec13 | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
Change In Receivables | Get a 7-Day Free Trial | 0.01 | - | - | -0.02 | -0.11 |
Zosano Pharma Quarterly Data | ||||||||||||||||||||
Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | |
Change In Receivables | Get a 7-Day Free Trial | - | - | - | - | -1.49 |
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.49 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zosano Pharma (OTCPK:ZSANQ) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Zosano Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2022 is calculated as:
Days Sales Outstanding | |||||
= | Accounts Receivable | / | Revenue | * | Days in Period |
= | 0.091 | / | 0.132 | * | 91 |
= | 62.91 |
2. In Ben Graham's calculation of liquidation value, Zosano Pharma's accounts receivable are only considered to be worth 75% of book value:
Zosano Pharma's liquidation value for the quarter that ended in Mar. 2022 is calculated as:
Liquidation Value | |||||||
= | Cash, Cash Equivalents, Marketable Securities | - | Total Liabilities | + | (0.75 * Accounts Receivable) | + | (0.5 * Total Inventories) |
= | 13.529 | - | 12.392 | + | 0.75 * 0.091 | + | 0.5 * 0 |
= | 1.21 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Zosano Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.
Christine Matthews | officer: Chief Financial Officer | C/O ZOSANO PHAMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555 |
Steven Lo | director, officer: Chief Executive Officer | C/O CORCEPT THERAPEUTICS, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94010 |
Donald J Kellerman | officer: VP, Clinical Dev & Med Affairs | INSPIRE PHARMACEUTICALS, INC.,, 4222 EMPEROR BLVD., STE. 470, DURHAM NC 27703-8466 |
Elaine Yang | director | C/O ZOSANO PHARMA CORPORATION, 34790 ARDENTECH COURT, FREMONT CA 94555 |
Kenneth Greathouse | director | 3260 WHIPPIE ROAD, UNION CITY CA 94587 |
Hayley Lewis | officer: See Remarks | C/O CARBYLAN THERAPEUTICS, INC., 3181 PORTER DRIVE, PALO ALTO CA 94304 |
Kathy M. Mcgee | director | C/O AVITA MEDICAL, 28159 AVENUE STANFORD, SUITE 220, VALENCIA CA 91355 |
Linda S Grais | director | 86 ALEJANDRA AVE, ATHERTON CA 94027 |
Joseph P Hagan | director | 3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037 |
Kleanthis G Xanthopoulos | director | 9050 CAMINO SANTA FE, SAN DIEGO CA 92121 |
John Peter Walker | director | 126 ISABELLA AVE, ATHERTON CA 94027 |
Aisling Capital Partners Iv, Lp | 10 percent owner | 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Aisling Capital Partners Iv Llc | 10 percent owner | 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Aisling Capital Iv, Lp | 10 percent owner | 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Andrew N Schiff | 10 percent owner | PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
From GuruFocus
By GuruFocusNews GuruFocusNews • 05-13-2022
By PRNewswire PRNewswire • 01-05-2022
By GuruFocusNews GuruFocusNews • 03-17-2022
By GuruFocusNews GuruFocusNews • 04-29-2022
By GuruFocusNews GuruFocusNews • 02-08-2022
By GuruFocusNews GuruFocusNews • 11-17-2021
By GuruFocusNews GuruFocusNews • 11-30-2021
By GlobeNewswire GlobeNewswire • 09-02-2021
By Marketwired Marketwired • 07-20-2021
By GuruFocusNews GuruFocusNews • 06-12-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.